(NURE) Nuveen Short-Term REIT - Ratings and Ratios
Real Estate, REITs, Equity, Investment, Assets
Description: NURE Nuveen Short-Term REIT
Nuveen Short-Term REIT ETF (BATS:NURE) is an exchange-traded fund that focuses on investing at least 80% of its net assets and borrowings in Real Estate Investment Trusts (REITs) that meet specific criteria. The underlying index is a subset of the Dow Jones U.S. Select REIT Index, comprising equity REITs listed on U.S. national securities exchanges, deriving at least 75% of their revenue from owning and operating real estate assets, and having a minimum market capitalization of $200 million.
The funds investment strategy is centered around REITs that are primarily involved in the ownership and operation of real estate assets, providing a relatively focused exposure to the real estate sector. As a non-diversified fund, NURE may have a higher concentration risk compared to diversified funds, which could result in higher volatility.
Analyzing the
Combining the insights from
To validate this forecast, it is crucial to monitor the funds tracking error, changes in AUM, and shifts in the underlying index composition. Additionally, keeping a close eye on interest rates, real estate market trends, and overall economic conditions will be essential in assessing NUREs future performance.
NURE ETF Overview
Market Cap in USD | 34m |
Category | Real Estate |
TER | 0.35% |
IPO / Inception | 2016-12-19 |
NURE ETF Ratings
Growth Rating | 3.62 |
Fundamental | - |
Dividend Rating | 60.7 |
Rel. Strength | -9.50 |
Analysts | - |
Fair Price Momentum | 26.73 USD |
Fair Price DCF | - |
NURE Dividends
Dividend Yield 12m | 4.22% |
Yield on Cost 5y | 6.26% |
Annual Growth 5y | 3.92% |
Payout Consistency | 82.8% |
Payout Ratio | % |
NURE Growth Ratios
Growth Correlation 3m | -34.7% |
Growth Correlation 12m | -84.2% |
Growth Correlation 5y | 23.9% |
CAGR 5y | 7.32% |
CAGR/Max DD 5y | 0.20 |
Sharpe Ratio 12m | -0.03 |
Alpha | -22.11 |
Beta | 0.582 |
Volatility | 22.15% |
Current Volume | 1.3k |
Average Volume 20d | 3.2k |
Stop Loss | 27.5 (-3.1%) |
What is the price of NURE shares?
As of August 13, 2025, the stock is trading at USD 28.38 with a total of 1,300 shares traded.Over the past week, the price has changed by -0.86%, over one month by -5.83%, over three months by -6.93% and over the past year by -7.54%.
Is Nuveen Short-Term REIT a good stock to buy?
Neither. Based on ValueRay´s Analyses, Nuveen Short-Term REIT is currently (August 2025) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of 3.62 and therefor a technical neutral rating according to historical growth.Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of NURE is around 26.73 USD . This means that NURE is currently overvalued and has a potential downside of -5.81%.
Is NURE a buy, sell or hold?
Nuveen Short-Term REIT has no consensus analysts rating.What are the forecasts/targets for the NURE price?
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | - | - |
Analysts Target Price | - | - |
ValueRay Target Price | 29.7 | 4.7% |
Last update: 2025-08-06 04:42
NURE Fundamental Data Overview
CCE Cash And Equivalents = unknown
Revenue TTM is 0, using Net Income TTM 0.0 + Cost of Revenue 0.0 = 0.0 USD
Beta = 1.04
Revenue TTM = 0.0 USD
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 34.1m USD (34.1m + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
FCF Yield = none (FCF TTM 0.0 / Enterprise Value 34.1m)
FCF Margin = unknown (Revenue TTM is 0)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 34.1m / Book Value Of Equity 0.0)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default)
NOPAT = 0.0 (EBIT 0.0, no tax applied on loss)
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown Debt (none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = none (Debt none / FCF TTM 0.0)
Total Stockholder Equity = unknown
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity none)
RoCE = unknown (Ebit 0.0 / (Equity none + L.T.Debt none))
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, Ebit 0.0)
WACC = unknown (E(34.1m)/V(0.0) * Re(8.16%)) + (D(none)/V(0.0) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 8.16% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow 0.0)
Additional Sources for NURE ETF
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle